Steroid-refractory chronic graft-versus-host disease: treatment options and patient management
Standard
Steroid-refractory chronic graft-versus-host disease: treatment options and patient management. / Wolff, Daniel; Fatobene, Giancarlo; Rocha, Vanderson; Kröger, Nicolaus; Flowers, Mary E.
In: BONE MARROW TRANSPL, Vol. 56, No. 9, 09.2021, p. 2079-2087.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Steroid-refractory chronic graft-versus-host disease: treatment options and patient management
AU - Wolff, Daniel
AU - Fatobene, Giancarlo
AU - Rocha, Vanderson
AU - Kröger, Nicolaus
AU - Flowers, Mary E
N1 - © 2021. The Author(s).
PY - 2021/9
Y1 - 2021/9
N2 - Chronic graft-versus-host disease (cGVHD) is one of the major causes of late mortality after allogenic hematopoietic stem cell transplantation. Moderate-to-severe cGVHD is associated with poor health-related quality of life and substantial disease burden. While corticosteroids with or without calcineurin inhibitors comprise the first-line treatment option, the prognosis for patients with steroid-refractory cGVHD (SR-cGVHD) remains poor. The mechanisms underlying steroid resistance are unclear, and there are no standard second-line treatment guidelines for patients with SR-cGVHD. In this review, we provide an overview on current treatment options of cGVHD and use a series of theoretical case studies to elucidate the rationale of choices of second- and third-line treatment options for patients with SR-cGVHD based on individual patient profiles.
AB - Chronic graft-versus-host disease (cGVHD) is one of the major causes of late mortality after allogenic hematopoietic stem cell transplantation. Moderate-to-severe cGVHD is associated with poor health-related quality of life and substantial disease burden. While corticosteroids with or without calcineurin inhibitors comprise the first-line treatment option, the prognosis for patients with steroid-refractory cGVHD (SR-cGVHD) remains poor. The mechanisms underlying steroid resistance are unclear, and there are no standard second-line treatment guidelines for patients with SR-cGVHD. In this review, we provide an overview on current treatment options of cGVHD and use a series of theoretical case studies to elucidate the rationale of choices of second- and third-line treatment options for patients with SR-cGVHD based on individual patient profiles.
U2 - 10.1038/s41409-021-01389-5
DO - 10.1038/s41409-021-01389-5
M3 - SCORING: Review article
C2 - 34218265
VL - 56
SP - 2079
EP - 2087
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 9
ER -